Chemoresistance in ovarian cancer (I)

Epithelial ovarian cancer (OC) presents unique challenges in diagnosis and treatment, characterized by vague symptoms and signs, delayed diagnosis and frequent advanced stage (ad). Initial the standard of care (SOC) treatment includes intensive cytoreductive surgery (CRS) and platinum-paclitaxel chemotherapy with/without adding anti-angiogenetic agent and/or following poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) maintenance therapy based on biomarker-guided recommendation, such as BRCA mutation and/or homologous recombination deficiency (HRD significance). However, OC-associated high recurrence rates and development of chemoresistance to recurrent OC (rOC) result in the therapeutic failure and…

• NS
  National Science and Technology Council

  Awards: 113-2314-B-075 -057 -MY3, 110-2314-B-075-016 MY3
• TV
  Taipei Veterans General Hospital

  Awards: V114C-039, V115C-095, V115B-008, V114B-015